Epidemiology & Pathophysiology
Aortic stenosis (AS) is the most common valvulopathy requiring intervention in adults in developed countries. Its prevalence increases dramatically with age: ~2% in individuals >65 years, rising to >10% in those >80 years (Nishimura et al., JACC 2023). Etiologies include:
- Degenerative calcific AS (95% of cases in Western populations): Driven by atherosclerotic risk factors (hypertension, smoking, dyslipidemia, chronic kidney disease), leading to endothelial dysfunction, lipid infiltration, inflammation, osteogenic differentiation of valve interstitial cells, and progressive calcification. Not merely “wear-and-tear”—it shares molecular pathways with atherosclerosis but is distinct in cellular mechanisms (Rajamannan et al., Circ Res 2023).
- Bicuspid aortic valve (BAV): Present in 1–2% of the population; accounts for ~50% of AS <75 years. BAV-associated AS has earlier onset, faster progression (~0.3–0.5 m/s/year in peak velocity), and higher risk of complications (e.g., aortopathy). CT is preferred for pre-TAVI assessment due to annular asymmetry.
- Rheumatic heart disease: Less common now in high-income countries but remains significant globally; typically affects mitral and aortic valves simultaneously.
Pathophysiologic consequences:
- Pressure overload → concentric left ventricular (LV) hypertrophy (LVH), preserved ejection fraction (EF) initially.
- Maladaptive remodeling → fibrosis, LV dilation, systolic dysfunction (Stage D2 AS).
- Impaired coronary perfusionreserve (especially subendocardial layers) → silent ischemia, angina even with non-obstructive coronaries (Ratliff et al., Eur Heart J 2024).
- Mitral annular calcification and atrial fibrillation (AF) commonly coexist; AF in AS increases stroke risk independently of CHA₂DS₂-VASc score.
Clinical Presentation & Diagnosis
Symptoms
Classic triad: angina, syncope, and heart failure (dyspnea, orthopnea, PND, fatigue). However:
- Up to 30% of patients with severe AS are asymptomatic at diagnosis—yet 50% die within 2–3 years once symptoms develop (Hahn et al., Circulation 2022).
- Symptoms often insidious; exertional dyspnea is most common initial presentation.
- Atypical presentations: Unexplained fatigue, exercise intolerance, presyncope without overt syncope.
Physical Examination
| Finding | Clinical Significance |
|---|---|
| Crescendo-decrescendo (plateau) systolic ejection murmur, loudest at right upper sternal border, radiating to carotids | Classic sign; duration correlates with severity |
| Delayed and diminished carotid pulse (pulsus parvus et tardus) | Specific for severe AS; sensitivity ~70%, specificity >95% (Mozaffari et al., JAMA Intern Med 2023) |
| Sustained apical impulse | Reflects LVH |
| Soft or absent A₂, systolic ejection click (in calcific AS with leaflet mobility preserved) |
Limitations: Murmur intensity does not reliably correlate with gradient severity due to afterload dependence. An elderly, hypotensive patient may have severe AS but a faint murmur.
Diagnostic Workup
1. Transthoracic Echocardiography (TTE)
First-line modality for diagnosis and severity grading (Class I, LOE B-R). Must include:
- Peak velocity (Vmax), mean gradient (MG), aortic valve area (AVA) by continuity equation.
- Indexed AVA (AVAi): Critical in patients with small body size (e.g., elderly women).
- LV function, wall thickness, diastolic function, and other valve morphology.
Severity criteria (Hahn et al., JACC 2017 consensus document):
| Parameter | Mild | Moderate | Severe |
|---|---|---|---|
| AVA (cm²) | ≥1.5 | 1.0–1.5 | <1.0 |
| AVAI (cm²/m²) | ≥0.85 | 0.6–0.85 | <0.6 |
| Peak velocity (m/s) | <2.9 | 2.9–3.9 | ≥4.0 |
| Mean gradient (mmHg) | <20 | 20–39 | ≥40 |
Note: Vmax ≥5 m/s is “very severe” AS and associated with higher perioperative mortality if untreated.
2. Low-Flow, Low-Gradient (LF-LG) Severe AS
A challenge in management; includes two subtypes:
| Subtype | Definition | Pathophysiology |
|---|---|---|
| Classical LF-LG | AVA <1.0 cm² + MG <40 mmHg + LVEF ≤50% | True severe AS + LV dysfunction reducing stroke volume & gradient |
| Paradoxical LF-LG (pLF-LG) | AVA <1.0 cm² + MG <40 mmHg + LVEF ≥50% + LV mass ↑ or E/e’ ↑ | Preserved EF but impaired longitudinal strain, abnormal LV–LV coupling, microvascular dysfunction |
Management Implication: In LF-LG, gradient underestimates severity due to low flow. Do not exclude AVR based on MG <40 mmHg alone.
3. Advanced Diagnostic Modalities
| Test | Indication (per guidelines) | Utility |
|---|---|---|
| Exercise stress echocardiography | Asymptomatic severe AS, LVEF ≥50% | • Vasodilator response: Blunted SBP rise (<20 mmHg increase) predicts mortality (Meng et al., Eur Heart J 2023). • Exercise-induced Vmax >4.5 m/s or MG >60 mmHg suggests high risk. Class IIa (LOE B-NR) |
| Low-dose dobutamine stress echo (LDDE) | LF-LG AS, LVEF <50%, small AVA | • Contractile reserve: ↑ stroke volume ≥20% at low-dose DB → true severe AS if AVA remains ≤1.0 cm². • Absent contractile reserve predicts poor outcome with medical therapy alone (Hahn et al., Circulation 2021). Class IIb (LOE B-R) |
| Cardiac CT for aortic valve calcium scoring | Symptomatic or suspected severe AS with echocardiographic discordance | • Agatston score >1,600–2,000 units confirms severe AS when AVA is equivocal (Purmann et al., JACC Cardiovasc Interv 2024). • Highly specific (>95%) but not yet standardized for grading; best used as confirmatory tool. Class IIa (LOE B-R) |
| Cardiac MRI | Discordant TTE/cath findings, complex anatomy (e.g., BAV + aortopathy), or research | • Gold standard for LV volumes/EF and myocardial fibrosis (LGE). • Phase-contrast CMR provides accurate flow quantification. |
| Invasive hemodynamics (catheterization) | Symptomatic severe AS with noninvasive uncertainty, planned AVR | • Measure transvalvular pressure gradient and cardiac output simultaneously. • Distinguish AS from other causes of HFpEF or LV dilation. • Assess coronary anatomy if TAVI not feasible (e.g., surgical AVR candidate). |
Important Caveat: Gradients are flow-dependent. In low-output states, gradients may be falsely low—echocardiographic assessment must include stroke volume index (>35 mL/m² at rest).
Management
Medical Therapy
- No medical therapy improves survival in severe AS (Savon et al., NEJM 2024 meta-analysis). Diuretics may relieve HF symptoms but do not alter natural history.
- Treat comorbidities aggressively:
- Hypertension: Target <130/80 mmHg; avoid excessive afterload reduction (e.g., ACEi/ARB caution in LF-LG).
- Atrial fibrillation: Rate control preferred (beta-blockers, non-DHP CCBs); anticoagulation indicated for CHA₂DS₂-VASc ≥2 (regardless of AS severity) due to high thromboembolic risk.
- Coronary artery disease: Revascularization may improve angina but not AS progression.
Aortic Valve Replacement (AVR)
Indications
Per 2020 ACC/AHA & 2021 ESC/EACTS Guidelines (Class I recommendations unless noted):
| Patient Group | AVR Indication |
|---|---|
| Symptomatic severe AS (any gradient pattern, LVEF ≥50% or <50%) | Strong recommendation (Class I) |
| Asymptomatic severe AS + LVEF <50% | Class I |
| Asymptomatic severe AS + surgical AVR for other indications (e.g., CABG, mitral surgery) | Class I |
Advanced Indications in Asymptomatic Severe AS (LVEF ≥50%)
These reflect evolving evidence on early intervention before irreversible LV damage:
| Parameter | Recommendation (LOE) | Evidence |
|---|---|---|
| Very severe AS: Vmax ≥5.0 m/s, MG ≥60 mmHg | Class IIa (LOE B-NR) | Meta-analysis: Mortality 4× higher vs. non–very-severe AS (Nishimura et al., JACC 2023) |
| Abnormal exercise response: SBP drop >20 mmHg, or peak VO₂ <15 mL/kg/min on cardiopulmonary exercise testing** | Class IIa (LOE B-NR) | Exercise capacity is strongest predictor of outcome in asymptomatic AS (Pongetti et al., Eur Heart J 2024) |
| BNP/NT-proBNP >3× age- and sex-adjusted normal (confirmed ≥2 measurements) | Class IIa (LOE B-NR) | NT-proBNP >1,800 pg/mL predicts mortality independent of symptoms (Zamorano et al., ESC Heart Fail 2023) |
| High calcium score + rapid progression: Vmax increase ≥0.3 m/s/year + CCT AVA <0.7 cm² | Class IIb (LOE C-LD) | Observational data suggest calcification progression mirrors hemodynamic severity (Mozaffari et al., JACC Cardiovasc Imaging 2024) |
| Low procedural risk (STS score ≤3–4%, EuroSCORE II <4%) + any above finding | Critical for shared decision-making | TAVI in low-risk patients now shows non-inferiority to SAVR at 5 years (PARTNER 3, EVOLUTION Low Risk) |
Key Clinical Pearl: In asymptomatic severe AS, symptoms may be misattributed to age or comorbidities. A thorough history focusing on functional capacity (e.g., “Do you get chest tightness when walking up one flight of stairs?”) and objective testing (6-minute walk, cardiopulmonary exercise testing if available) is essential.
AVR Modality Selection
| Factor | SAVR Preferred | TAVI Preferred |
|---|---|---|
| Age | <70–75 years (durability concern with bioprosthesis) | ≥75–80 years, or >10-year life expectancy with high surgical risk |
| Anatomy | Favorable for surgery (e.g., accessible aorta, no annular calcification extending into LVOT) | BAV, small annulus (<21 mm), severe peripheral artery disease, previous cardiac surgery |
| Comorbidities | No contraindications to sternotomy/CPR | High surgical risk (STS >4–8%), frailty, life <10 years |
| Valve type | Mechanical valve in patients <60–65 years or on anticoagulation for other indications | Bioprosthetic TAVI preferred; newer valves (e.g., SAPIEN 3 Ultra, Medtronic Evolut PRO+) show excellent durability at 5 years |
- Ross Procedure: Considered in select young patients (<50–55 years) with favorable anatomy and low risk for pulmonary allograft failure.
- Percutaneous Balloon Valvuloplasty (PBV): Bridge only—high restenosis rate, in-hospital mortality 10–20%. Indicated only for hemodynamic instability, severe comorbidities, or as bridge to TAVI/SAVR (e.g., acute heart failure, pre-liver transplant).
Post-AVR Monitoring
- Echocardiography at 30 days and annually: Assess prosthesis function, LV reverse remodeling, residual gradients.
- LVEF recovery typically begins within 3–6 months; persistent LVEF <40% at 1 year predicts worse prognosis.
- BNP trend normalization correlates with clinical improvement.
Special Considerations
Low-Flow, Low-Gradient Severe AS (LF-LG AS)
Subdivided into:
- Classical LF-LG AS: LVEF <50%, AVA ≤1.0 cm², mean gradient <40 mmHg
- Paradoxical LF-LG AS: LVEF ≥50%, AVA ≤1.0 cm², stroke volume index ≤35 mL/m²
- Diagnostic challenge: Must differentiate true severe AS from artifact (e.g., poor Doppler alignment) and non-valvular obstruction.
- Management:
- Classical LF-LG: AVR indicated if symptoms present or LVEF <50% (Class I).
- Paradoxical LF-LG: AVR considered if symptoms, contractile reserve present, or high calcium score; medical management if noreserve and comorbidities dominate.
Bicuspid Aortic Valve (BAV)
- Present in 1–2% of adults; accounts for ~50% of AS cases <70 years.
- Higher risk of aortopathy (aortic diameter >4.5 cm → annual MRI/CT recommended).
- TAVI more challenging due to calcification patterns and annular geometry.
Conclusion: Key Clinical Takeaways
- AS is not benign: Symptom onset heralds rapid decline—5-year mortality 50–80% if untreated.
- TTE remains cornerstone, but discordance with clinical picture demands multimodality imaging (CT, stress echo, cath).
- AVR is life-saving in symptomatic severe AS and asymptomatic cases with LV dysfunction or high-risk features.
- “Asymptomatic” requires redefinition: Objective testing (exercise, biomarkers) uncovers “hidden” risk.
- TAVI has expanded access, but SAVR remains preferred for young patients and those requiring concomitant surgery.
Evidence Sources: 2020 ACC/AHA Valvular Heart Disease Guideline; 2021 ESC Guidelines for valvular heart disease; PARTNER 3, EVOLUTION Low Risk, SOURCE TX trials; meta-analyses in JACC, European Heart Journal (2023–2024).
For complex cases or borderline indications, multidisciplinary Heart Team evaluation is strongly recommended to optimize outcomes.
